Tranylcypromine (DB00752): A Comprehensive Clinical and Pharmacological Monograph

Executive Summary

Tranylcypromine is a potent, non-selective, and irreversible monoamine oxidase inhibitor (MAOI) with a unique chemical structure derived from amphetamine.[1] First approved by the U.S. Food and Drug Administration (FDA) in 1961, it occupies a critical, albeit niche, position in the psychiatric armamentarium.[3] Its primary clinical indication is for the treatment of major depressive disorder (MDD) in adult patients who have not responded adequately to other antidepressant therapies.[4] It is particularly valued for its high efficacy in cases of treatment-resistant depression (TRD) and atypical depression, where its broad mechanism of action may succeed after more selective agents have failed.[1]

The therapeutic utility of tranylcypromine is inextricably linked to a demanding and complex safety profile. Its irreversible inhibition of MAO necessitates strict adherence to a tyramine-restricted diet to prevent potentially fatal hypertensive crises.[1] Furthermore, its co-administration with a wide range of medications, particularly serotonergic agents like selective serotonin reuptake inhibitors (SSRIs), is absolutely contraindicated due to the risk of life-threatening serotonin syndrome.[1] These risks mandate a high level of expertise from the prescribing clinician and a deep commitment to education and adherence from the patient.

Beyond its established role in psychiatry, tranylcypromine is the subject of contemporary research for its activity as an inhibitor of lysine-specific demethylase 1 (LSD1), an epigenetic enzyme implicated in the pathogenesis of certain cancers. This has led to investigational clinical trials exploring its potential as an antineoplastic agent, particularly in hematologic malignancies, signaling a modern relevance that extends beyond its original therapeutic purpose.[1] Tranylcypromine thus represents a classic high-risk, high-reward therapeutic agent, whose powerful efficacy in severe illness justifies the rigorous management its use demands.

Introduction and Historical Context

Origins and Discovery

The history of tranylcypromine is a compelling example of serendipity in drug discovery. It was first synthesized in 1948 as a structural analog of amphetamine, with its development driven by the goal of creating a novel central nervous system stimulant with a different profile.[1] Its initial clinical investigations were not for depression but as a potential nasal decongestant, a therapeutic avenue where it proved ineffective.[5] The pivotal discovery of its potent monoamine oxidase-inhibiting properties did not occur until 1959, over a decade after its initial synthesis.[1] This finding repositioned the compound entirely, placing it within the first generation of antidepressant medications and leading to its subsequent development for psychiatric indications. This origin story, rooted in amphetamine chemistry, provides a fundamental context for understanding tranylcypromine's unique pharmacological profile, which includes inherent stimulant-like effects alongside its primary MAO-inhibiting action.

Regulatory Journey

Tranylcypromine received its initial U.S. FDA approval in 1961 and was marketed under the brand name Parnate.[3] Its early years on the market were fraught with significant regulatory challenges that nearly led to its withdrawal. In 1964, reports of severe hypertensive crises and deaths from subarachnoid hemorrhage emerged in patients taking the drug.[10] This crisis precipitated intensive investigation that ultimately uncovered the critical food-drug interaction with tyramine, a pressor amine found in aged and fermented foods. The discovery transformed a drug-specific safety issue into a foundational principle of pharmacology, establishing the necessity of dietary restrictions for all non-selective MAOIs.

The drug faced a second major regulatory test in 1971 under the FDA's Drug Efficacy Study Implementation (DESI) initiative, which re-evaluated the effectiveness of drugs approved prior to 1962.[10] At the time, tranylcypromine lacked the robust, randomized controlled trial (RCT) evidence that was becoming the new gold standard. However, the FDA was ultimately persuaded by compelling clinical testimony regarding its profound efficacy in patients with severe, melancholic depression for whom no other treatments were effective. The agency's decision to allow its continued marketing, based heavily on clinical experience in the absence of definitive RCT data, was a pivotal moment. This regulatory history is a microcosm of the evolution of modern pharmaceutical regulation, highlighting a historical period where powerful clinical observation could hold significant weight against emerging, stricter evidence standards. It underscores the perception of tranylcypromine's exceptional efficacy, which was deemed sufficient to warrant navigating its considerable risks.

Current Status

Today, tranylcypromine is universally classified as a prescription-only medicine (e.g., ℞-only in the US, POM in the UK, Schedule 4 in Australia).[1] It remains an important, though not widely used, therapeutic option. Its use is largely confined to specialist psychiatric practice for managing the most difficult-to-treat mood disorders. Its survival and continued availability are a legacy of its recognized potency, serving as a critical last-line agent when newer, safer medications have proven insufficient.

Chemical Identity and Physicochemical Properties

Nomenclature and Identifiers

Tranylcypromine is a small molecule drug classified as a substituted phenethylamine and a member of the cyclopropane class.[1] As a therapeutic agent, it is a racemic mixture, comprising equal parts of the (1R,2S)- and (1S,2R)-enantiomers.[2] The drug is most commonly formulated and administered as its sulfate salt, tranylcypromine sulfate.[8] Its key chemical and physical identifiers are consolidated in Table 1.

Structural Analysis

The chemical structure of tranylcypromine is (±)-trans-2-phenylcyclopropan-1-amine. It is a propylamine derivative formed from the cyclization of the side chain of amphetamine.[2] This structural relationship is fundamental to its pharmacology, directly contributing to its secondary stimulant-like properties, which distinguish it from other MAOIs like the hydrazines (e.g., phenelzine). The chiral centers are located on the cyclopropane ring, and the trans configuration is critical for its biological activity.[2]

Manufacturing Process

The synthesis of tranylcypromine is a multi-step process. It begins with the reaction of stabilized styrene and ethyl diazoacetate to produce ethyl 2-phenylcyclopropanecarboxylate. This ester is then hydrolyzed with sodium hydroxide to form 2-phenylcyclopropanecarboxylic acid. The trans isomer is separated from the cis isomer by recrystallization. The carboxylic acid is converted to its carbonyl chloride using thionyl chloride. This intermediate then undergoes a Curtius rearrangement with sodium azide to form an isocyanate, which is subsequently hydrolyzed with hydrochloric acid to yield the final product, 2-phenylcyclopropanamine. The amine base is then reacted with a half-molar quantity of sulfuric acid to produce the stable and clinically used sulfate salt.[9]

Physical and Chemical Properties

Tranylcypromine free base is a liquid at room temperature, whereas its sulfate salt is a white crystalline powder.[9] The sulfate salt may possess a faint odor resembling cinnamaldehyde and has a slightly acidic taste.[12] It is soluble in water, and its physicochemical properties, such as a low molecular weight and a favorable LogP value, are consistent with good oral bioavailability and the ability to cross the blood-brain barrier, as predicted by Lipinski's Rule of Five.[3]

Table 1: Chemical and Physical Identifiers of Tranylcypromine

Property	Value	Source(s)
DrugBank ID	DB00752	2
Type	Small Molecule	2
IUPAC Name	2-phenylcyclopropan-1-amine	3
Synonyms	Parnate, SKF 385, (±)-trans-2-phenylcyclopropylamine	1
CAS Number	155-09-9 (free base)	12
	13492-01-8 (sulfate salt)	14
Molecular Formula		2
Molecular Weight	133.19 g/mol	2
Physical Form	White crystalline powder (sulfate salt)	12
Melting Point	28 °C (free base)	9
pKa (Strongest Basic)	8.24 - 9.62 (Predicted)	9
Water Solubility	48 mg/mL	15
LogP	1.36 - 1.5	3
SMILES	C1C(C1N)C2=CC=CC=C2	12
InChIKey	AELCINSCMGFISI-UHFFFAOYSA-N	12

Comprehensive Pharmacology

Pharmacodynamics: Mechanism of Action

The pharmacodynamic profile of tranylcypromine is complex, characterized by a potent primary mechanism of action augmented by important secondary pharmacological effects.

Primary Mechanism: MAO Inhibition

Tranylcypromine functions as a non-selective and irreversible inhibitor of monoamine oxidase (MAO), an enzyme critical for the degradation of monoamine neurotransmitters.[1] It inhibits both major isoforms of the enzyme, MAO-A and MAO-B, with a slight preference for MAO-B.[1] These isoforms have distinct substrate specificities and tissue distributions:

• MAO-A is found predominantly in the gut, liver, and other peripheral tissues, as well as within the brain. It is the primary enzyme responsible for metabolizing serotonin, norepinephrine, epinephrine, dopamine, and dietary tyramine.[2] Inhibition of MAO-A is considered most relevant to the antidepressant effect.[2]
• MAO-B is located primarily in the brain and platelets and preferentially metabolizes phenylethylamine and dopamine.[2]

The inhibition is irreversible because tranylcypromine forms a stable, covalent bond with the flavin adenine dinucleotide (FAD) cofactor of the enzyme, rendering it permanently inactive.[1] Consequently, the biological effect of the drug persists long after it has been cleared from the plasma. Restoration of enzymatic function is not achieved through drug dissociation but requires the de novo synthesis of new MAO enzyme molecules, a process that can take several days to weeks.[1]

Neurochemical Consequences

By blocking the primary metabolic pathway for monoamines, tranylcypromine leads to a significant increase in the presynaptic concentrations of serotonin (), norepinephrine (NE), and dopamine (DA) in the central nervous system.[2] This accumulation enhances the amount of neurotransmitter available for release into the synapse, thereby amplifying monoaminergic neurotransmission. This broad enhancement of amine signaling is the theoretical basis for its potent antidepressant and anxiolytic properties.[2]

Secondary Pharmacological Actions

Tranylcypromine's clinical profile cannot be fully explained by MAO inhibition alone. Its structural relationship to amphetamine confers additional, distinct pharmacological properties:

• Amphetamine-like Effects: It acts as a weak norepinephrine reuptake inhibitor and dopamine-releasing agent, particularly at higher therapeutic doses.[5] This contributes to its characteristic activating or stimulant-like effects, such as insomnia and agitation, and may also play a role in its rapid onset of action and potential for abuse.[1]
• Histone Demethylase (LSD1) Inhibition: Tranylcypromine is also a potent inhibitor of lysine-specific demethylase 1 (LSD1/KDM1A), an epigenetic enzyme that removes methyl groups from histones, thereby regulating gene expression.[1] LSD1 is overexpressed in various cancers, and its inhibition by tranylcypromine de-represses the transcription of target genes, leading to anti-proliferative effects. This mechanism is entirely separate from its MAO-inhibiting activity and forms the basis for its investigation as an antineoplastic agent.[8]

Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion (ADME)

The pharmacokinetics of tranylcypromine are characterized by rapid absorption and elimination, which stands in stark contrast to its long-lasting pharmacodynamic effects. This disconnect is a critical concept for its safe clinical use.

Absorption

Following oral administration, tranylcypromine is efficiently absorbed, with peak plasma concentrations () typically reached within 1 to 2 hours.[1] Some individuals exhibit a biphasic absorption pattern, with a secondary peak occurring at 2 to 3 hours post-dose. It has been postulated that this may be due to differential rates of absorption for the two stereoisomers of the racemic drug, although this hypothesis requires further confirmation.[2]

Distribution

The volume of distribution () for tranylcypromine is reported to be between 1.1 and 5.7 L/kg.[2] This value, being significantly larger than the volume of total body water, indicates that the drug distributes extensively into tissues outside of the plasma compartment.

Metabolism

Tranylcypromine undergoes primary metabolism in the liver.[2] The main metabolic pathways involve hydroxylation and N-acetylation, yielding metabolites such as 4-hydroxytranylcypromine, N-acetyltranylcypromine, and N-acetyl-4-hydroxytranylcypromine.[1] These metabolites are significantly less potent as MAO inhibitors than the parent compound. It is important to correct a historical misconception: while structurally related to amphetamine, tranylcypromine is not metabolized to amphetamine in humans.[1]

Excretion and Half-Life

Tranylcypromine has a remarkably short pharmacokinetic half-life (), ranging from 1.5 to 3.2 hours in individuals with normal renal and hepatic function.[1] This rapid clearance from the bloodstream creates a profound pharmacokinetic/pharmacodynamic (PK/PD) disconnect. The clinical effects of the drug are not governed by its plasma concentration but by the slow turnover rate of the MAO enzyme it irreversibly inhibits. A clinician who mistakenly assumes the drug's effects cease shortly after it is cleared from the body would be at high risk of causing a serious drug interaction. This pharmacological principle is the reason for the mandatory 1- to 2-week washout period required when switching to or from other interacting medications; this interval is necessary to allow for the synthesis of new MAO enzymes, not for the clearance of the drug itself.[4]

Clinical Applications and Therapeutic Efficacy

FDA-Approved Indication: Major Depressive Disorder (MDD)

The primary FDA-approved indication for tranylcypromine is the treatment of major depressive disorder (MDD) in adult patients who have not responded adequately to other antidepressant therapies.[4] Due to its significant potential for serious adverse reactions and drug interactions, it is explicitly not recommended for the initial treatment of MDD.[4] The official indication specifies MDD

without melancholia, although a wealth of clinical experience and historical evidence supports its potent efficacy in severe, melancholic, and endogenous forms of depression.[2]

Meta-analytic data have confirmed that tranylcypromine is superior to placebo and demonstrates efficacy comparable to that of older comparator drugs, such as tricyclic antidepressants (TCAs).[5] A significant gap in the evidence base is the lack of modern, large-scale RCTs comparing tranylcypromine directly with newer first-line agents like SSRIs and serotonin-norepinephrine reuptake inhibitors (SNRIs).[19]

Off-Label and Investigational Uses in Psychiatry

Treatment-Resistant Depression (TRD)

The most critical clinical role for tranylcypromine is in the management of treatment-resistant depression (TRD). It is widely regarded by specialists as one of the most powerful options available for patients who have failed multiple trials of other antidepressants, and in some cases, even electroconvulsive therapy (ECT).[19]

The landmark Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study reported a low response rate for tranylcypromine.[19] However, this finding is subject to significant criticism. Tranylcypromine was used in the final step of the treatment algorithm, meaning it was administered to the most profoundly refractory patient population, in whom the likelihood of response to any agent was low.[19] Furthermore, the mean dose used in the trial (36.9 mg/day) was conservative and likely suboptimal for this difficult-to-treat population.[19] In contrast, specialist-led studies and clinical experience show that higher doses, sometimes exceeding 100 mg/day, are often required to achieve remission in TRD, with response rates reported to be over 50%.[19] This discrepancy highlights that the efficacy of a potent drug like tranylcypromine is highly dependent on expert dose optimization and appropriate patient selection, factors that may not be fully captured in large, generalized pragmatic trials.

Atypical Depression

There is a strong evidence base supporting the preferential efficacy of MAOIs, including tranylcypromine, for atypical depression.[1] This subtype of depression is characterized by mood reactivity (the ability to feel better in response to positive events), hypersomnia, hyperphagia (increased appetite), leaden paralysis (a heavy feeling in the limbs), and rejection sensitivity.[5] Some research suggests that individuals with atypical depression may have higher baseline MAO activity, providing a potential biological rationale for the superior efficacy of MAOIs in this population.[19]

Anxiety Disorders

Tranylcypromine is also used off-label for treatment-resistant anxiety disorders, including social anxiety disorder and panic disorder, where it can be effective when first- and second-line treatments have failed.[1]

Bipolar Depression

The use of tranylcypromine for bipolar depression is an active area of investigation. Standard antidepressants carry a risk of inducing a switch from depression to mania in patients with bipolar disorder. Some evidence suggests that tranylcypromine may have a lower risk of causing this manic switch compared to other antidepressants like TCAs, making it a potentially valuable option for this challenging condition.[21]

Emerging Investigational Uses in Oncology

A new frontier for tranylcypromine is its potential application in oncology, based on its mechanism as an LSD1 inhibitor.[1] LSD1 is an epigenetic enzyme that is overexpressed in various cancers and is crucial for tumor cell proliferation and survival. Completed Phase 1 clinical trials have evaluated tranylcypromine, often in combination with other agents like all-trans retinoic acid (ATRA), for the treatment of hematologic malignancies such as Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS).[7] These trials have primarily focused on elderly, medically non-fit patients who have failed prior treatments. While the objective response rates have been modest, the combination therapy was found to be feasible and resulted in disease stabilization for a substantial portion of patients, indicating a signal of activity and justifying further research in this area, likely with more powerful and specific LSD1 inhibitors derived from the tranylcypromine scaffold.[28]

Dosage, Administration, and Clinical Management

The safe and effective use of tranylcypromine requires careful patient selection, meticulous dosing and titration, and rigorous management of medication transitions.

Dosage Forms

Tranylcypromine is commercially available as tranylcypromine sulfate in 10 mg oral tablets. These tablets are typically round, rose-red, film-coated, and debossed with "PARNATE" on one side and "SB" on the other.[4]

Dosing and Administration

Dosage must be individualized based on patient response and tolerability.

• Standard Dosing for MDD: The recommended starting dosage is typically 30 mg per day, administered in divided doses (e.g., 15 mg in the morning and 15 mg in the early afternoon) to minimize side effects like insomnia.[4] Some clinicians prefer a more conservative start at 10 mg daily, titrating upwards every 1 to 3 weeks.[5] The dose can be adjusted based on clinical response, with a usual FDA-approved maximum of 60 mg per day.[18]
• High-Dose Strategies for TRD: In specialist settings for treatment-resistant depression, doses are often cautiously escalated beyond the 60 mg/day limit. Doses up to 120 mg/day or higher have been used under close medical supervision, including frequent blood pressure monitoring, to achieve a therapeutic response in highly refractory patients.[19]

Clinical Management

Patient Screening

Prior to initiating therapy, several screening steps are mandatory:

1. Blood Pressure Measurement: A baseline blood pressure must be established, and patients must be monitored for changes throughout treatment.[4]
2. Screening for Bipolar Disorder: Patients should be screened for a personal or family history of bipolar disorder, mania, or hypomania to assess the risk of antidepressant-induced manic switching.[4]

Medication Switching Protocols

Medication transitions are periods of highest risk. The irreversible nature of MAO inhibition dictates the need for strict washout periods to prevent severe drug interactions.

Table 2: Summary of Dosing and Medication Switching Guidelines

Parameter	Guideline	Source(s)
Indication	Major Depressive Disorder (not first-line)	4
Starting Dose	10-30 mg/day in divided doses	4
Titration	Increase by 10 mg/day every 1-3 weeks as tolerated	23
Usual Therapeutic Range	30-60 mg/day	18
Max Dose (FDA-Approved)	60 mg/day	18
Max Dose (Specialist TRD)	Up to 120 mg/day or higher with close monitoring	21
Switching TO Tranylcypromine
From most antidepressants	Discontinue previous drug and wait 4-5 half-lives	4
From Fluoxetine	Wait at least 5 weeks after discontinuation	5
Switching FROM Tranylcypromine
To another MAOI or contraindicated drug (e.g., SSRI, SNRI, TCA)	Wait at least 1-2 weeks after discontinuation	4

Discontinuation of Therapy

Abrupt discontinuation of tranylcypromine, especially from higher doses or after long-term use, can precipitate a withdrawal syndrome that may include agitation, confusion, and delirium. Therefore, treatment should be discontinued via a slow, gradual dose reduction.[4]

Safety Profile and Risk Mitigation

The use of tranylcypromine is governed by a stringent safety profile that requires comprehensive risk mitigation strategies. The drug's adverse effects are a direct reflection of its potent and broad pharmacology.

FDA Black Box Warning: Suicidality

In line with all antidepressant medications, tranylcypromine carries an FDA Black Box Warning concerning an increased risk of suicidal thoughts and behaviors.[5]

• Population at Risk: The warning applies to children, adolescents, and young adults (up to age 24) being treated for MDD and other psychiatric disorders.[5]
• Monitoring Requirements: Patients in this age group must be monitored closely for clinical worsening, the emergence of suicidal ideation, and unusual changes in behavior, particularly during the initial 1 to 2 months of therapy and following any dosage adjustments.[5]
• Pediatric Use: Tranylcypromine is not approved for use in pediatric patients, and its use in this population is not recommended.[5]

Adverse Drug Reactions

The adverse effect profile can be understood by categorizing reactions based on their underlying mechanism.

• Effects of MAO Inhibition: The most common side effect is dizziness secondary to orthostatic hypotension, occurring in up to 17% of patients.[1] This results from the blunting of norepinephrine-mediated vasoconstrictive reflexes. Other common effects related to altered monoamine levels include tachycardia, sexual dysfunction (impotence, delayed ejaculation), weight loss, dry mouth, and constipation.[1]
• Amphetamine-like Effects: The drug's structural similarity to amphetamine contributes to activating side effects such as insomnia, agitation, restlessness, and tremor.[1] These effects are often dose-dependent and can be managed by administering the last dose of the day in the early afternoon.
• Serious and Rare Reactions: The most severe risks are typically associated with interactions. These include hypertensive crisis and serotonin syndrome. Other rare but serious reactions include hepatotoxicity (jaundice), blood dyscrasias, and the activation of mania or hypomania in susceptible individuals with bipolar disorder.[1]

Contraindications and Precautions

Use of tranylcypromine is absolutely contraindicated in several conditions where the risk of a catastrophic adverse event is unacceptably high.

• Absolute Contraindications:
• Pheochromocytoma or other catecholamine-secreting tumors (e.g., paraganglioma).[4]
• Confirmed or suspected cerebrovascular disease, cardiovascular disease, hypertension, or a history of stroke.[1]
• History of liver disease.[18]
• History of severe or frequent headaches.[18]
• Use in Special Populations:
• Geriatric: Elderly patients may be more sensitive to orthostatic hypotension and are more likely to have comorbid conditions or reduced renal/hepatic function that necessitate caution and potential dose adjustments.[18]
• Pregnancy and Lactation: Tranylcypromine is classified as Australian Pregnancy Category B2.[1] There are no adequate studies in pregnant women, and it has been associated with adverse fetal outcomes in animal studies. Its use should be reserved for situations where the potential benefit to the mother clearly outweighs the potential risk to the fetus.[5] It is not known if the drug is excreted in human milk, so a decision must be made whether to discontinue nursing or the drug.[18]
• Renal Impairment: Caution is advised, as reduced clearance may lead to increased drug exposure and a higher risk of adverse effects.[18]

Critical Drug and Food Interactions

The safe use of tranylcypromine is critically dependent on the strict avoidance of specific food and drug interactions.

The Tyramine-Induced Hypertensive Crisis

This is the most well-known and dangerous interaction associated with MAOIs.

• Pathophysiology: Tyramine is a naturally occurring monoamine found in high concentrations in aged, fermented, pickled, or spoiled foods.[1] Under normal circumstances, MAO-A in the intestinal wall and liver rapidly metabolizes dietary tyramine, preventing its systemic absorption.[5] When a patient is taking tranylcypromine, this enzymatic barrier is disabled. Ingested tyramine is absorbed into the bloodstream, where it acts as a potent indirect sympathomimetic. It is taken up into sympathetic nerve terminals and triggers a massive, uncontrolled release of stored norepinephrine.[1] This surge of norepinephrine, which itself cannot be efficiently degraded due to MAO inhibition, causes severe vasoconstriction, leading to a rapid and dangerous spike in blood pressure known as a hypertensive crisis.[4]
• Clinical Presentation and Management: The crisis typically presents with a sudden, severe, throbbing occipital headache, which may be followed by palpitations, neck stiffness, nausea, vomiting, sweating, and photophobia. In severe cases, it can lead to intracranial hemorrhage and death.[5] This is a medical emergency requiring immediate treatment with a rapid-acting antihypertensive agent.
• Dietary Management: Patient education on diet is the cornerstone of prevention. The tyramine restriction must be maintained throughout treatment and for at least two weeks after discontinuing tranylcypromine to allow for MAO enzyme regeneration.[5]

Table 3: Tyramine Dietary Guidelines for Patients on Tranylcypromine

Foods to AVOID (High Tyramine Risk)	Foods to Use with CAUTION (Moderate/Variable Risk)	Foods Generally Considered SAFE (Low Tyramine)
Cheeses: All aged cheeses (e.g., Cheddar, Swiss, Parmesan, blue cheese, Brie)	Fruits/Vegetables: Avocados, bananas, raspberries (especially if overripe)	Cheeses: Fresh cheeses (e.g., cottage cheese, cream cheese, ricotta, mozzarella)
Meats/Fish: Aged, cured, smoked, fermented, or pickled meats/fish (e.g., salami, pepperoni, sausage, pickled herring, smoked salmon)	Soy Products: Tofu, miso soup	Meats/Fish: Freshly prepared meat, poultry, and fish; canned fish packed in oil or water
Alcohol: All tap/draft beers, red wine (especially Chianti), sherry, liqueurs	Caffeine: Coffee, tea, cola, chocolate (in large amounts)	Grains: Breads, cereals, pasta, rice
Yeast/Protein Extracts: Brewer's yeast, Marmite, Vegemite	Nuts: Peanuts, Brazil nuts	Dairy: Milk, yogurt, sour cream (if fresh)
Other: Sauerkraut, fava or broad bean pods, soy sauce, all spoiled or improperly stored foods		Fruits/Vegetables: Most fresh, canned, or frozen fruits and vegetables

Sources: [5]

Pharmacodynamic Drug-Drug Interactions

These interactions arise from the combined effects of two drugs on the same physiological systems and are often severe.

Table 4: Clinically Significant Drug-Drug Interactions with Tranylcypromine

Interaction Type / Drug Class	Mechanism & Clinical Consequence	Management	Source(s)
Risk of Serotonin Syndrome
SSRIs, SNRIs, most TCAs, Triptans, Dextromethorphan, Meperidine, Tramadol, Linezolid, St. John's Wort	Massive accumulation of serotonin due to combined reuptake inhibition/release and blocked metabolism. Potentially fatal.	ABSOLUTELY CONTRAINDICATED	1
Risk of Hypertensive Crisis
Sympathomimetics (Pseudoephedrine, Phenylephrine, Amphetamines, Methylphenidate)	Potentiation of pressor effects due to blocked metabolism and/or enhanced release of norepinephrine.	ABSOLUTELY CONTRAINDICATED	1
Levodopa, Dopamine	Increased availability of norepinephrine precursor, leading to excessive synthesis and potential pressor effects.	ABSOLUTELY CONTRAINDICATED	1
Buspirone	Mechanism unclear, but associated with significant blood pressure elevations.	ABSOLUTELY CONTRAINDICATED	18
Use with Extreme Caution
Opioids (other than meperidine)	Risk of additive CNS and respiratory depression. Some may have serotonergic properties.	Avoid or use test doses of small amounts with close monitoring.	30
CNS Depressants (Alcohol, Benzodiazepines, Barbiturates, Antihistamines)	Additive sedation, cognitive and motor impairment.	Avoid or use with extreme caution. Advise patients against driving.	30
Potential for Altered Metabolism
CYP2A6 Substrates (e.g., Nicotine)	Inhibition of CYP2A6 by tranylcypromine can increase substrate levels and toxicity.	Monitor for adverse effects of the substrate drug.	1
CYP2C19 & CYP2D6 Substrates	Inhibition of these enzymes can increase levels of numerous co-administered drugs.	Monitor for adverse effects of the substrate drug; dose reduction may be needed.	5

Pharmacokinetic Drug-Drug Interactions

Tranylcypromine is an inhibitor of several cytochrome P450 (CYP) enzymes, including CYP2A6, CYP2C19, and CYP2D6.[1] This can lead to clinically significant interactions by reducing the metabolism of co-administered drugs that are substrates for these enzymes. This can increase the plasma concentrations and potential toxicity of a wide range of medications, including some antipsychotics, beta-blockers, and other agents. While these interactions are generally less acute than the pharmacodynamic ones, they require careful consideration during medication management.

Conclusion and Future Perspectives

Tranylcypromine stands as a powerful and enduring legacy medication in psychopharmacology. Its identity is defined by a profound duality: it offers unparalleled efficacy for some of the most severe and refractory forms of depression, yet its use is constrained by a demanding safety profile that requires unwavering diligence from both clinicians and patients. The irreversible inhibition of MAO, coupled with its amphetamine-like properties, creates a broad neurochemical action that appears uniquely suited to depressive states that are unresponsive to more targeted, modern agents. Its continued place in the therapeutic armamentarium is a testament to its high efficacy, which, for a select patient population, provides a level of relief unattainable with other treatments.

The future of tranylcypromine is likely to evolve along several distinct paths. In psychiatry, its role will probably remain that of a specialist, third-line agent for TRD and atypical depression. The key to its future use in this domain will be the development of strategies for precision medicine—identifying biomarkers or clinical profiles that can predict which patients are most likely to benefit from its potent, broad-spectrum mechanism. This would allow for more targeted application, maximizing its benefits while minimizing exposure for those unlikely to respond.

The most exciting new frontier lies outside of psychiatry. The discovery of tranylcypromine's potent activity as an LSD1 inhibitor has opened up an entirely new field of investigation in oncology. While tranylcypromine itself may be a prototype, it serves as a chemical scaffold for the development of a new class of more specific and powerful epigenetic drugs for cancer therapy. Furthermore, the neuroprotective potential of MAO inhibitors, through the reduction of oxidative stress, suggests that tranylcypromine or related compounds could be explored for their utility in neurodegenerative disorders, a field with immense unmet need. Tranylcypromine, therefore, is not merely a relic of a past era of psychopharmacology but a compound whose complex biology continues to inspire new therapeutic possibilities.

Works cited

1. Tranylcypromine - Wikipedia, accessed October 1, 2025, https://en.wikipedia.org/wiki/Tranylcypromine
2. Tranylcypromine: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed October 1, 2025, https://go.drugbank.com/drugs/DB00752
3. tranylcypromine | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY, accessed October 1, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5281
4. PARNATE® (tranylcypromine) tablets, for oral use - accessdata.fda.gov, accessed October 1, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/012342s064lbl.pdf
5. Tranylcypromine - StatPearls - NCBI Bookshelf, accessed October 1, 2025, https://www.ncbi.nlm.nih.gov/books/NBK459162/
6. Tranylcypromine in mind (Part II): Review of clinical pharmacology and meta-analysis of controlled studies in depression - PubMed, accessed October 1, 2025, https://pubmed.ncbi.nlm.nih.gov/28579071/
7. Tranylcypromine Completed Phase 1 Trials for Acute Myeloid Leukemia / Leukemias / Myelodysplastic Syndrome Treatment | DrugBank Online, accessed October 1, 2025, https://go.drugbank.com/drugs/DB00752/clinical_trials?conditions=DBCOND0029883%2CDBCOND0035632%2CDBCOND0028333&phase=1&purpose=treatment&status=completed
8. Definition of tranylcypromine sulfate - NCI Drug Dictionary, accessed October 1, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/tranylcypromine-sulfate
9. tranylcypromine | 155-09-9 - ChemicalBook, accessed October 1, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB8926373.htm
10. Tranylcypromine (Parnate): A Brief History and a Enduring Anomaly, accessed October 1, 2025, https://www.psychotropical.com/tranylcypromine-parnate-a-brief-history/
11. Parnate | healthdirect, accessed October 1, 2025, https://www.healthdirect.gov.au/medicines/brand/amt,4229011000036103/parnate
12. Tranylcypromine | C9H11N | CID 5530 - PubChem, accessed October 1, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Tranylcypromine
13. Showing metabocard for Tranylcypromine (HMDB0014890) - Human Metabolome Database, accessed October 1, 2025, https://hmdb.ca/metabolites/HMDB0014890
14. Tranylcypromine sulfate | CAS#13492-01-8 | MAOI - MedKoo Biosciences, accessed October 1, 2025, https://www.medkoo.com/products/8851
15. tranylcypromine - Drug Central, accessed October 1, 2025, https://drugcentral.org/drugcard/2715
16. CAS 155-09-9: Tranylcypromine - CymitQuimica, accessed October 1, 2025, https://cymitquimica.com/cas/155-09-9/
17. Tranylcypromine sulfate | DrugBank Online, accessed October 1, 2025, https://go.drugbank.com/salts/DBSALT000960
18. Tranylcypromine (oral route) - Side effects & dosage - Mayo Clinic, accessed October 1, 2025, https://www.mayoclinic.org/drugs-supplements/tranylcypromine-oral-route/description/drg-20073226
19. Tranylcypromine: Its Pharmacology, Safety, and Efficacy - Psychiatry Online, accessed October 1, 2025, https://psychiatryonline.org/doi/10.1176/appi.ajp-rj.2020.150402
20. Tranylcypromine Based Lysine-Specific Demethylase 1 Inhibitor: Summary and Perspective | Journal of Medicinal Chemistry - ACS Publications, accessed October 1, 2025, https://pubs.acs.org/doi/abs/10.1021/acs.jmedchem.0c00919
21. Tranylcypromine: A Powerful and Underrated Option for Treatment-Resistant Depression, accessed October 1, 2025, https://phillyintegrative.com/blog/tranylcypromine-for-depression
22. Clinically Relevant Drug Interactions with Monoamine Oxidase Inhibitors - PMC, accessed October 1, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9680847/
23. Tranylcypromine (Parnate) | National Alliance on Mental Illness (NAMI), accessed October 1, 2025, https://www.nami.org/about-mental-illness/treatments/mental-health-medications/types-of-medication/tranylcypromine-parnate/
24. Tranylcypromine Uses, Side Effects & Warnings - Drugs.com, accessed October 1, 2025, https://www.drugs.com/mtm/tranylcypromine.html
25. Reducing the Burden of Difficult-to-Treat Major Depressive Disorder: Revisiting Monoamine Oxidase Inhibitor Therapy - Psychiatrist.com, accessed October 1, 2025, https://www.psychiatrist.com/pcc/reducing-burden-difficult-treat-major-depressive/
26. High Dose Tranylcypromine Therapy for Refractory Depression - ResearchGate, accessed October 1, 2025, https://www.researchgate.net/publication/20445043_High_Dose_Tranylcypromine_Therapy_for_Refractory_Depression
27. Study Details | NCT01430455 | Tranylcypromine Treatment of Bipolar Depression, accessed October 1, 2025, https://www.clinicaltrials.gov/study/NCT01430455
28. Phase I Study of the LSD1 Inhibitor Tranylcypromine (TCP) in Combination with All-Trans Retinoic Acid (ATRA) and Low-Dose Cytarabine (LDAC) in Elderly, Medically Non-Fit Patients with AML or High-Risk MDS (TRANSATRA trial) | Blood | American Society of Hematology, accessed October 1, 2025, https://ashpublications.org/blood/article/140/Supplement%201/9087/491762/Phase-I-Study-of-the-LSD1-Inhibitor
29. Parnate (Tranylcypromine): Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed October 1, 2025, https://www.rxlist.com/parnate-drug.htm
30. Parnate (tranylcypromine) dosing, indications, interactions, adverse effects, and more, accessed October 1, 2025, https://reference.medscape.com/drug/parnate-tranylcypromine-342952
31. Tranylcypromine: MedlinePlus Drug Information, accessed October 1, 2025, https://medlineplus.gov/druginfo/meds/a682088.html
32. Tranylcypromine Advanced Patient Information - Drugs.com, accessed October 1, 2025, https://www.drugs.com/cons/tranylcypromine.html
33. PARNATE - accessdata.fda.gov, accessed October 1, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/012342s061lbl.pdf
34. Tranylcypromine Sulfate or Parnate: Food, Alcohol, Supplements and Drug Interactions - ScriptSave WellRx, accessed October 1, 2025, https://www.wellrx.com/tranylcypromine-sulfate/lifestyle-interactions/
35. Tranylcypromine and Alcohol/Food Interactions - Drugs.com, accessed October 1, 2025, https://www.drugs.com/food-interactions/tranylcypromine.html
36. Tranylcypromine Tablets: Uses & Side Effects - Cleveland Clinic, accessed October 1, 2025, https://my.clevelandclinic.org/health/drugs/18950-tranylcypromine-tablets
37. Showing BioInteractions for Tranylcypromine (DB00752) | DrugBank Online, accessed October 1, 2025, https://go.drugbank.com/drugs/DB00752/biointeractions